Company: INDP
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001641172-25-006429
Chunk: 41

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 41
---
 programs comply with applicable legal and regulatory requirements. The Board does not believe that its role in the oversight of our risks affects the Board’s leadership structure.

Clawback Policy

Our Board of Directors has adopted a Policy for Recovery of Erroneously Awarded Compensation (the “Clawback Policy”), in accordance with the Nasdaq listing standards and Exchange Act Rule 10D-1, which applies to our current and former executive officers. Under the Clawback Policy, we are required to recoup the amount of any Erroneously Awarded Compensation (as defined in the Clawback Policy) on a pre-tax basis within a specified lookback period in the event of any Financial Restatement (as defined in the Clawback Policy), subject to limited impracticability exception.

Policies and Practices Related to the Grant of Certain Equity Awards

From time to time, we award stock
options to our employees, including the named executive officers. Historically, the Company we awarded new-hire option grants on or soon
after a new hire’s employment start date and periodic annual refresh employee option grants, which refresh grants are typically
approved at a meeting of the compensation committee or board. Non-employee directors receive automatic initial and annual stock option
grants, at the time of a director’s appointment or election to the board and at the time of each annual meeting of our stockholders,
respectively. For additional information on our non-employee director compensation policy see below under the heading, “Director
Compensation.”

We do not otherwise maintain any written
policies on the timing of awards of stock options, stock appreciation rights, or similar instruments with option-like features. It is
the Company’s practice to not grant any awards to its named executive officers when in possession of any material nonpublic information,
and to wait until such material nonpublic information has been fully disclosed, widely disseminated to the public and at least two full
business days has passed after such material nonpublic information has been disclosed.

Code of Ethics

We have a written Code of Business Conduct and Ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. We have posted a current copy of the Code of Business Conduct and Ethics on our website, www.indaptusrx.com, in the “Investors” section under “Corporate Governance.” In addition, we intend to post on our website all disclosures that are required by law or the rules of Nasdaq concerning any amendments to